Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EQ101

Other · developed by Equillium

Phase 2 Most advanced trial (none active)
EQ Developer
1 Registered trials

What is EQ101?

EQ101 is a drug studied in alopecia areata, including alopecia totalis and alopecia universalis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Equillium (EQ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05589610 Phase 2 Alopecia Areata Completed EQ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AlopeciaAlopecia AreataAlopecia TotalisAlopecia Universalis

More from Equillium

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EQ page.

Follow EQ, the company behind EQ101

See EQ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EQ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.